<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: While national guidelines recommend <z:chebi fb="2" ids="35457">ACE inhibitor</z:chebi> (ACEI) or angiotensin receptor blocker (ARB) therapy in patients with <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0000112'>nephropathy</z:hpo>, guidelines concerning elderly patients with <z:mp ids='MP_0002055'>diabetes</z:mp> have not endorsed these drugs </plain></SENT>
<SENT sid="1" pm="."><plain>We sought to assess the nephroprotective efficacy and safety of ARB therapy in elderly patients by conducting age-specific subgroup analyses using data from the Reduction of Endpoints in <z:mp ids='MP_0002057'>NIDDM</z:mp> with the <z:chebi fb="0" ids="2719,48432">Angiotensin II</z:chebi> <z:chebi fb="68" ids="48706">Antagonist</z:chebi> <z:chebi fb="0" ids="6541">Losartan</z:chebi> (RENAAL) study </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: We studied 1,513 patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0000112'>nephropathy</z:hpo> who randomly received either <z:chebi fb="0" ids="6541">losartan</z:chebi> or placebo </plain></SENT>
<SENT sid="3" pm="."><plain>We tested for effect modification by age of the effect of <z:chebi fb="0" ids="6541">losartan</z:chebi> on the incidence of the predefined end points (doubling of serum <z:chebi fb="0" ids="16737">creatinine</z:chebi>, <z:hpo ids='HP_0003774'>end-stage renal disease</z:hpo> [<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e>], or <z:hpo ids='HP_0011420'>death</z:hpo>) and the risk of adverse events </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Of 1,513 participants, 421 (27.8%) were aged &gt;65 years (maximum age 74 years) </plain></SENT>
<SENT sid="5" pm="."><plain>Age did not modify the efficacy of <z:chebi fb="0" ids="6541">losartan</z:chebi> in reducing the risk of the primary outcome, a composite of doubling of serum <z:chebi fb="0" ids="16737">creatinine</z:chebi>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e>, or <z:hpo ids='HP_0011420'>death</z:hpo> (P(interaction) = 0.66) or its individual components (<z:hpo ids='HP_0000001'>all</z:hpo> P(interaction) &gt; 0.44) </plain></SENT>
<SENT sid="6" pm="."><plain>In patients aged &gt;65 years, <z:chebi fb="0" ids="6541">losartan</z:chebi> reduced the risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e> by 50% (95% CI 30-81, P = 0.005) </plain></SENT>
<SENT sid="7" pm="."><plain>We found no evidence that older patients were more likely to experience adverse events from <z:chebi fb="0" ids="6541">losartan</z:chebi> such as a rise in serum <z:chebi fb="0" ids="16737">creatinine</z:chebi> or <z:hpo ids='HP_0002153'>hyperkalemia</z:hpo> than younger patients </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Elderly patients had the same level of benefits and risks as younger patients from treatment with <z:chebi fb="0" ids="6541">losartan</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>Underuse of ACEI and ARB therapy in elderly patients because of the perceived lack of efficacy or a greater risk of adverse events appears unjustified </plain></SENT>
</text></document>